Technological advances in analytical instrumentation and computing systems have allowed
many industries to better monitor and control business critical processes. This has enabled
proactive, not reactive approaches to real-time quality assurance and product release. Until
the advent of QbD and subsequent PAT initiatives, pharmaceutical and related industries were
not fully equipped with the right guidance and supporting architecture to gain the benefits of
modern, state-of-the-art quality control and assurance systems.
